A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia a patients

Haematologica

Volumn 101, Issue 10, 2016, Pages 1159-1169

  Hazendonk, Hendrika ^a   Fijnvandraat, Karin ^b   Lock, Janske ^a   Driessens, Mariëtte ^c   van der Meer, Felix ^d   Meijer, Karina ^e   Kruip, Marieke ^f   van Gorkom, Britta Laros ^g   Peters, Marjolein ^b   de Wildt, Saskia ^a,g   Leebeek, Frank ^f   Cnossen, Marjon ^a   Mathôt, Ron ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Netherlands Hemophilia Patient Organization (NVHP)   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; BLOOD GROUP ABO SYSTEM; BLOOD GROUP ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLEARANCE; ERYTHROCYTE TRANSFUSION; HEMOPHILIA A; HUMAN; PERIOPERATIVE PERIOD; PHARMACOKINETIC PARAMETERS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STRUCTURAL MODEL; SUBSTITUTION THERAPY; AGE; BLOOD GROUP ABO SYSTEM; BODY WEIGHT; CLINICAL TRIAL; DOSE CALCULATION; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; THEORETICAL MODEL;

ABO BLOOD-GROUP SYSTEM; AGE FACTORS; BLOOD GROUP ANTIGENS; BODY WEIGHT; CHILD, PRESCHOOL; DRUG DOSAGE CALCULATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PERIOPERATIVE CARE; RETROSPECTIVE STUDIES;

EID: 84989315273     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.136275     Document Type: Article

References (45)

1. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ. 2012;344:e2707.
2. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3): 413-420.
3. Leebeek FWG, Mauser-Bunschoten EP, Editors. [Richtlijn Diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen]. Van Zuiden Communications BV. 2009;1-197.
4. Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program. 2011;2011:413-418.
5. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia. 2003;9 Suppl 1:111-115; dicussion 116.
6. Feldman BM, Aledort L, Bullinger M, et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia. 2007;13(6):745-749.
7. Nederlandse Zorgautoriteit. [Onderzoek naar de toegankelijkheid en betaalbaarheid van geneesmiddelen in de medisch special- istische zorg]. Available from: https://www.nza.nl/publicaties/1048188/Onderzoeksrapport__Toegankelijkheid_en_betaalbaarheid_van_geneesmiddelen_in_de_medisch_specialistis, 29-06-2015:1-110.
8. Traore AN, Chan AK, Webert KE, et al. First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia. 2014; 20(4):e251-259.
9. Hazendonk HC, Lock J, Mathot RA, et al. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost. 2016;14(3):468-478.
10. Hazendonk HCAM, Lock J, Fijnvandraat K, et al. A retrospective observational multi-center study on peri-operative Factor IX consumption in Hemophilia B ("OPTI-CLOT" studies). J Thromb Haemost. 2013;11:Suppl 2.
11. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997;3(2):96-101.
12. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65(10):989-998.
13. Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612-618.
14. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working G. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.
15. Longo G, Messori A, Morfini M, et al. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol. 1989;30(3):140-149.
16. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247(4 Pt2):F632-636.
17. Peters AM, Snelling HL, Glass DM, Bird NJ. Estimation of lean body mass in children. Br J Anaesth. 2011;106(5):719-723.
18. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes. 1985;9(2):147-153.
19. Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood. 1995;86(10):3676-3684.
20. U.S. Department of Health and Human Services FaDA. Guidance for Industry. Population Pharmacokinetics.
21. Boeckmann AJ, Sheiner LB, Beal SL. NON-MEM Users Guide. NONMEM Project Group. 2011;University of California at San Francisco (ICON Development Solutions Ellicott City, Maryland):1-165.
22. Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NON-MEM. Comput Methods Programs Biomed. 1999;58(1):51-64.
23. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1): 72-79.
24. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332.
25. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-569.
26. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol. 2002;117(1):247-248.
27. Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost. 2003;90(6):1088-1093.
28. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486-495.
29. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-151.
30. Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia. 2002;8(3):170-177.
31. Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia. 2006;12(3):212-217.
32. Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia. 2002;8(5):629-634.
33. Mulcahy R, Walsh M, Scully MF. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre. Haemophilia. 2005;11(3):208-215.
34. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia. 2001;7(1):117-122.
35. Stieltjes N, Altisent C, Auerswald G, et al. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia. 2004;10(5):452-458.
36. Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet. 1992;22(5):385-395.
37. Noe DA. A mathematical model of coagulation factor VIII kinetics. Haemostasis. 1996;26(6):289-303.
38. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood. 1995;85(11):3150-3157.
39. Kahlon A, Grabell J, Tuttle A, et al. Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals. Haemophilia. 2013;19(5):758-764.
40. Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia. 1999;5(2):88-95.
41. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 2000;83(1):65-69.
42. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol. 1995;91(2):474-476.
43. Klarmann D, Eggert C, Geisen C, et al. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion. 2010;50(7):1571-1580.
44. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92(11):3983-3996.
45. Hazendonk HC, van Moort I, Fijnvandraat K, et al. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. Thromb Haemost. 2015;114(3):639-644.